Roche reports 17.4% passive stake in Freenome

Freenome, Inc. (FRNM) has a significant shareholder group led by Roche entities that jointly report beneficial ownership of a large minority stake in the company.

Rhea-AI Filing Summary

Freenome, Inc. (FRNM) has a significant shareholder group led by Roche entities that jointly report beneficial ownership of a large minority stake in the company. Roche Holdings, Inc., Roche Finance Ltd, and Roche Holding Ltd (the “Reporting Persons”) have filed a Schedule 13G disclosing their ownership in Freenome’s common stock.

The Reporting Persons report beneficial ownership of 18,692,766 shares of Freenome common stock, representing 17.4% of the class, based on 107,446,814 shares outstanding as of July 20, 2026. Of these, 18,055,686 shares are held of record by Roche Holdings, Inc. and 637,080 shares are held of record by Roche Finance Ltd. The Reporting Persons state they have 0 shares with sole voting or dispositive power and 18,692,766 shares with shared voting and dispositive power.

Key Figures

Shares beneficially owned: 18,692,766 shares of common stock Percent of class beneficially owned: 17.4 % Shares held by Roche Holdings, Inc.: 18,055,686 shares of common stock +4 more

7 metrics

Shares beneficially owned 18,692,766 shares of common stock Beneficially owned by the Roche reporting group

Percent of class beneficially owned 17.4 % Portion of Freenome common stock reported as owned by the Roche group

Shares held by Roche Holdings, Inc. 18,055,686 shares of common stock Held of record by Roche Holdings, Inc.

Shares held by Roche Finance Ltd 637,080 shares of common stock Held of record by Roche Finance Ltd

Shares outstanding 107,446,814 shares of common stock Freenome shares outstanding as of July 20, 2026

Shared voting power 18,692,766 shares Shares over which the Reporting Persons have shared voting power

Shared dispositive power 18,692,766 shares Shares over which the Reporting Persons have shared dispositive power

Key Terms

Schedule 13G, beneficially own, shared voting power, shared dispositive power, +1 more

5 terms

Schedule 13G regulatory

"This is filed jointly by Roche Holdings, Inc., Roche Finance Ltd and Roche Holding Ltd"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficially own financial

"Roche Finance Ltd may be deemed to beneficially own the shares held by Roche Holdings, Inc."

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

shared voting power financial

"Shared Voting Power 18,692,766.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 18,692,766.00"

Joint Filing Agreement regulatory

"A Joint Filing Agreement is attached as Exhibit 99.1."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much of Freenome, Inc. (FRNM) do the Roche entities beneficially own?

The Roche reporting group beneficially owns 18,692,766 shares of Freenome, Inc. common stock, representing 17.4% of the outstanding common shares, based on 107,446,814 shares outstanding as of July 20, 2026.

Which Roche entities are reporting ownership in Freenome, Inc. (FRNM)?

The filing is made jointly by Roche Holdings, Inc., Roche Finance Ltd, and Roche Holding Ltd. Roche Holdings, Inc. is a wholly owned subsidiary of Roche Finance Ltd, which in turn is a wholly owned subsidiary of Roche Holding Ltd.

How are the 18,692,766 Freenome (FRNM) shares held by the Roche group allocated?

The reported 18,692,766 shares consist of 18,055,686 shares of Freenome common stock held of record by Roche Holdings, Inc. and 637,080 shares held of record by Roche Finance Ltd.

What voting and dispositive powers do the Roche entities report for their Freenome (FRNM) shares?

The Reporting Persons state they have 0 shares with sole voting power and 18,692,766 shares with shared voting power. They also have 0 shares with sole dispositive power and 18,692,766 shares with shared dispositive power.

What share count did Freenome (FRNM) report as outstanding for this Schedule 13G calculation?

The 17.4% ownership percentage is calculated based on 107,446,814 shares of Freenome’s common stock outstanding as of July 20, 2026, as reported by the company in a Current Report on Form 8-K filed on July 24, 2026.

What type of filing did the Roche entities submit regarding Freenome, Inc. (FRNM)?

They submitted a Schedule 13G, which reports beneficial ownership of Freenome common stock by Roche Holdings, Inc., Roche Finance Ltd, and Roche Holding Ltd, and includes a Joint Filing Agreement as Exhibit 99.1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 04:32 PM EDT Accepted by SEC EDGAR 09/01/2026 - 04:32 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Freenome, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

35661P100

(CUSIP Number)

07/20/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 35661P100

1

Names of Reporting Persons

Roche Holdings, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 18,692,766.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 18,692,766.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

18,692,766.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

17.4 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: The securities reported in Items 6, 8 and 9 herein consist of (i) 18,055,686 shares of common stock held of record by Roche Holdings, Inc. and (ii) 637,080 shares of common stock held of record by Roche Finance Ltd. The percentage in Item 11 is calculated based upon 107,446,814 shares of the Issuer's common stock outstanding as of July 20, 2026, as reported by the Issuer in its Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 24, 2026.

SCHEDULE 13G

CUSIP Number(s): 35661P100

1

Names of Reporting Persons

Roche Finance Ltd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 18,692,766.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 18,692,766.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

18,692,766.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

17.4 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: The securities reported in Items 6, 8 and 9 herein consist of (i) 18,055,686 shares of common stock held of record by Roche Holdings, Inc. and (ii) 637,080 shares of common stock held of record by Roche Finance Ltd. The percentage in Item 11 is calculated based upon 107,446,814 shares of the Issuer's common stock outstanding as of July 20, 2026, as reported by the Issuer in its Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 24, 2026.

SCHEDULE 13G

CUSIP Number(s): 35661P100

1

Names of Reporting Persons

Roche Holding Ltd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 18,692,766.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 18,692,766.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

18,692,766.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

17.4 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: The securities reported in Items 6, 8 and 9 herein consist of (i) 18,055,686 shares of common stock held of record by Roche Holdings, Inc. and (ii) 637,080 shares of common stock held of record by Roche Finance Ltd. The percentage in Item 11 is calculated based upon 107,446,814 shares of the Issuer's common stock outstanding as of July 20, 2026, as reported by the Issuer in its Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 24, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Freenome, Inc.
(b)	Address of issuer's principal executive offices: Genesis Marina, 3300 Marina Blvd, Brisbane, CA 94005
Item 2.
(a)	Name of person filing: This Schedule 13G is filed jointly by Roche Holdings, Inc., Roche Finance Ltd and Roche Holding Ltd (collectively, the "Reporting Persons"). Roche Holdings, Inc. is a wholly owned subsidiary of Roche Finance Ltd, which is a wholly owned subsidiary of Roche Holding Ltd. A Joint Filing Agreement is attached as Exhibit 99.1.
(b)	Address or principal business office or, if none, residence: Roche Holdings, Inc.: 1 DNA Way, Mailstop 49, South San Francisco, California 94080Roche Finance Ltd: Grenzacherstrasse 122, CH 4070 Basel, SwitzerlandRoche Holding Ltd: Grenzacherstrasse 124, CH 4070 Basel, Switzerland
(c)	Citizenship: Roche Holdings, Inc.: Delaware; Roche Finance Ltd: Switzerland; Roche Holding Ltd: Switzerland
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP Number(s): 35661P100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the responses to Item 9 on the attached cover pages. Roche Finance Ltd may be deemed to beneficially own the shares held by Roche Holdings, Inc., its wholly owned subsidiary, and Roche Holding Ltd may be deemed to beneficially own the shares held by both Roche Finance Ltd and Roche Holdings, Inc.
(b)	Percent of class: See the responses to Item 11 on the attached cover pages.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: See the responses to Item 6 on the attached cover pages.
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: See the responses to Item 8 on the attached cover pages.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Roche Holdings, Inc.

Signature:	/s/ Anjna Mehta
Name/Title:	Anjna Mehta, Authorized Signatory
Date:	09/01/2026

Roche Finance Ltd

Signature:	/s/ Anja Harmeier
Name/Title:	Anja Harmeier, Authorized Signatory
Date:	09/01/2026

Signature:	/s/ Peter Trybus
Name/Title:	Peter Trybus, Authorized Signatory
Date:	09/01/2026

Roche Holding Ltd

Signature:	/s/ Claudia Bockstiegel
Name/Title:	Claudia Bockstiegel, Authorized Signatory
Date:	09/01/2026

Signature:	/s/ Peter Trybus
Name/Title:	Peter Trybus, Authorized Signatory
Date:	09/01/2026

Exhibit Information

Exhibit 99.1 - Joint Filing Agreement